two groups of aml patients ( n1 = 63 , n2 = 20 ) and two groups of all patients ( n1 = 33 , n2 = 15 ) were treated using polychemotherapy protocols which in each leukaemia subtype differed mainly in adriblastin administration being either in bolus form ( 30 mg/m2/day i.v . ) or fractional form at the beginning 20 mg i.v. , then 6 mg/m2 every 6 h .
C0023467
aml
C0023418
subtype